ArticleScientific reports2026
Broad spectrum antimicrobial nanoparticles with low toxicity to prevent biofilm formation on urologic devices.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Antimicrobial coatings for medical implants are critical in preventing device failures and infections. Antibiotics are often used as prophylactic or coatings but fail to prevent biofilm formation and drive antibiotic resistance. Herein, the antibacterial and antibiofilm activities of different polyhydroxy fullerene-based metal nanoparticle coatings on polyurethane discs were quantified after exposure to Escherichia coli. Gold-silver nanoparticles (GSNP) exhibited superior antibacterial activity compared to other silver-containing nanoparticles. GSNPs were evaluated against Escherichia coli, Enterococcus faecalis, Enterobacter hormaechei, Klebsiella oxytoca, Staphylococcus aureus and Staphylococcus epidermidis isolated from ureteral stents and inflatable penile prostheses and achieved 100% reduction of all tested urologic pathogens at physiological relevant bacterial loads (p < 0.0001). GSNPs inactivate bacteria by reactive oxygen species production with the estimated minimum inhibitory concentrations slightly higher for Gram-positive than Gram-negative bacteria with highest observed for S. epidermidis at 2.23 µg/mL. Safety studies with fibroblasts demonstrate that GSNPs at estimated minimum inhibitory concentrations have minimal effect (< 20%) on cell viability. Further, the GSNPs were able to reduce bacteria by six logs more than commercial nanoparticles. GSNPs represent a promising strategy for preventing biofilm formation on medical devices and implants due to their broad antibacterial activity and low toxicity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.